Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

Publisher： Karger

E-ISSN： 2296-5262|36|10|554-558

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.10, 2013-09, pp. : 554-558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra   Geyer Charles E  

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?

By Santini Daniele   Vincenzi Bruno   Tonini Giuseppe  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 14-17

Karger

Access to resources Recommend Favorite

Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies

By  

Oncology, Vol. 78, Iss. 2, 2010-04 ,pp. : 141-149

Karger

Access to resources Recommend Favorite